It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Comorbidities such as anemia or hypertension and physiological factors related to exertion can influence a patient’s hemodynamics and increase the severity of many cardiovascular diseases. Observing and quantifying associations between these factors and hemodynamics can be difficult due to the multitude of co-existing conditions and blood flow parameters in real patient data. Machine learning-driven, physics-based simulations provide a means to understand how potentially correlated conditions may affect a particular patient. Here, we use a combination of machine learning and massively parallel computing to predict the effects of physiological factors on hemodynamics in patients with coarctation of the aorta. We first validated blood flow simulations against in vitro measurements in 3D-printed phantoms representing the patient’s vasculature. We then investigated the effects of varying the degree of stenosis, blood flow rate, and viscosity on two diagnostic metrics – pressure gradient across the stenosis (ΔP) and wall shear stress (WSS) - by performing the largest simulation study to date of coarctation of the aorta (over 70 million compute hours). Using machine learning models trained on data from the simulations and validated on two independent datasets, we developed a framework to identify the minimal training set required to build a predictive model on a per-patient basis. We then used this model to accurately predict ΔP (mean absolute error within 1.18 mmHg) and WSS (mean absolute error within 0.99 Pa) for patients with this disease.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Duke University, Department of Biomedical Engineering, Durham, USA (GRID:grid.26009.3d) (ISNI:0000 0004 1936 7961)
2 Brigham and Women’s Hospital, Harvard Medical School, Boston, USA (GRID:grid.26009.3d)
3 Lawrence Livermore National Laboratory, Livermore, USA (GRID:grid.250008.f) (ISNI:0000 0001 2160 9702)
4 Arizona State University, Department of Biological and Health Systems Engineering, Tempe, USA (GRID:grid.215654.1) (ISNI:0000 0001 2151 2636)
5 Dana-Farber Cancer Institute, Department of Department of Data Sciences, Boston, USA (GRID:grid.65499.37) (ISNI:0000 0001 2106 9910); Harvard T. H. Chan School of Public Health, Department of Biostatistics, Boston, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); Harvard University, Department of Stem Cell and Regenerative Biology, Cambridge, USA (GRID:grid.38142.3c) (ISNI:000000041936754X); The Broad Institute of Harvard and MIT, Cambridge, USA (GRID:grid.66859.34)